RE:RE:RE:RE:RE:You are amazing ClaridgeHempdoc ... Thanks for posting the
Neuro-Oncology Advances journal paper on our Rutherrin in the GBM indication.
It's another hint that the GBM indication is around the corner. Dr. Lilge once mentioned that when it's innovations in unchartered territories, FDA/HC regulatories bodies ask them to publish in peer-reviewed journals. If you noticed, this article is "open", so it can receive comments by neuro-oncologists.
__________
Hempdoc - (6/1/2019 8:10:07 PM) RE:RE:RE:RE:You are amazing Claridge Having such invaluable technology/IP makes any near-term valuation of this company impossible, & the reason I hope TLT holds off on any JV/takeover as long as they possibly can. Not only will their laser/dosimetry evolve, so will their development of new organometallic complexes. Fortunately for us, Rutherrin is a great start & has few serious rivals. IMO, it is the perfect Trojan Horse, a form of chemical subterfuge that gifts cancer its main staple for growth (iron) in a well-veiled poison (Rutherrin). Then shine a little light & voila...
Claridge was correct in saying that we are very privileged (& even blessed) to have been presented with such an opportunity. It is a rare & precious occasion to be able to invest in something that can potentially save millions of lives while also affording the “real” potential to make a personal fortune along the way...this is certainly no Trojan Horse for shareholders. Good luck..
This was recently published in Neuro-Oncology Advances journal:
https://academic.oup.com/noa/advance-article/doi/10.1093/noajnl/vdz006/5499230?searchresult=1